Holitilin, 400 mg capsules 28 pcs

Pharmacodynamics

Choline alphoscerate, is a cholinomimetic of central action with predominant effect on the central nervous system.

The preparation contains 40.5% choline which is released from the compound in the brain; choline is involved in the biosynthesis of acetylcholine (one of the main mediators of nerve excitation). Alphoscerate is biotransformed to glycerophosphate, which is a precursor of phospholipids.

Acetylcholine has a positive effect on nerve impulse transmission, and glycerophosphate participates in the synthesis of phosphatidylcholine (membrane phospholipid), as a result improving membrane elasticity and receptor function.

Choline alphoscerate increases metabolic processes and activates structures of the reticular formation of the brain.

It has preventive and corrective effects on factors of involutional psycho-organic syndrome, such as changes in the phospholipid composition of neuronal membranes and decreased cholinergic activity.

Pharmacodynamic studies have shown that choline alphoscerate acts on synaptic, including cholinergic transmission of nerve impulse (neurotransmission), neuronal membrane plasticity and receptor function.

Pharmacokinetics

Absorption when ingested is 88%; easily penetrates the blood-brain barrier, accumulates primarily in the brain (concentration in the brain reaches 45% of blood levels), lungs and liver; 85% is excreted by the lungs as carbon dioxide, the remaining amount (15%) is excreted by the kidneys and through the intestines.

It does not affect the reproductive cycle, has no teratogenic and mutagenic effects.

Indications

Cerebral circulation disorders of ischemic type (acute and recovery periods) and hemorrhagic type (recovery period).

Psychoorganic syndrome against the background of involutional and degenerative processes of the brain.

Consequences of cerebrovascular insufficiency or primary and secondary cognitive impairment in the elderly, characterized by memory impairment, confusion, disorientation, decreased motivation and initiative, decreased concentration.

Behavioral and affective disorders in old age: emotional lability, increased irritability, decreased interest; senile pseudomelancholia.

Multi-infarct dementia.

Pharmacological effect

Pharmacodynamics

Choline alfoscerate is a centrally acting cholinomimetic with a predominant effect on the central nervous system.

The drug contains 40.5% choline, released from a compound in the brain; choline is involved in the biosynthesis of acetylcholine (one of the main mediators of nervous excitation). Alphoscerate is biotransformed to glycerophosphate, which is a precursor of phospholipids.

Acetylcholine has a positive effect on the transmission of nerve impulses, and glycerophosphate is involved in the synthesis of phosphatidylcholine (membrane phospholipid), resulting in improved membrane elasticity and receptor function.

Choline alfoscerate enhances metabolic processes and activates the structures of the reticular formation of the brain.

It has a preventive and corrective effect on the factors of involutional psychoorganic syndrome, such as changes in the phospholipid composition of neuronal membranes and a decrease in cholinergic activity.

Pharmacodynamic studies have shown that choline alfoscerate acts on synaptic, including cholinergic transmission of nerve impulses (neurotransmission), neuronal membrane plasticity and receptor function.

Pharmacokinetics

Absorption when taken orally – 88%; easily penetrates the blood-brain barrier, accumulates mainly in the brain (concentration in the brain reaches 45% of the level in the blood), lungs and liver; 85% is excreted by the lungs in the form of carbon dioxide, the rest (15%) is excreted by the kidneys and through the intestines.

Does not affect the reproductive cycle, does not have teratogenic or mutagenic effects.

Special instructions

During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Active ingredient

Choline alphoscerate

Composition

One capsule contains:

active ingredient:

choline alfoscerate hydrate, calculated as choline alfoscerate 400.00 mg;

excipients:

purified water 109.00 mg,

povidone K-15 1.00 mg, macrogol (polyethylene glycol 400) until the capsule contents weigh 640.00 mg;

soft gelatin capsule 250.000 mg, including: purified water* 151.64 mg, glycerol (glycerin) 41.090 mg, gelatin 164.313 mg, yellow iron oxide dye 0.770 mg, red iron oxide dye 0.154 mg, black iron oxide dye 0.169 mg, methyl parahydroxybenzoate 1.166 mg, propyl parahydroxybenzoate 0.164 mg, sorbitol 41.500 mg, titanium dioxide 0.674 mg.

* – absent in the finished product.

Pregnancy

The use of the drug Cholitilin during pregnancy and breastfeeding is contraindicated.

Contraindications

Hypersensitivity, hemorrhagic stroke (acute stage), pregnancy, lactation, children under 18 years of age.

Side Effects

From the digestive system: gastritis, gastric ulcer, pharyngitis.

From the nervous system: nervousness, cerebral ischemia, convulsions, hyperkinesia, dizziness.

Other: allergic reactions, increased urination.

Interaction with other drugs

No drug interactions have been established.

Overdose

Symptoms: nausea.
The severity of dose-dependent side effects may increase.
Treatment: symptomatic therapy.
The effectiveness of dialysis has not been established.

Manufacturer

Artlife LLC, Russia